TLK2 and ovarian serous adenocarcinoma: Similarly, in UWB1.289, a BRCA1-mutant high-grade serous ovarian cancer (HGSOC) cell line, TLK1 or TLK2 depletion decreased sensitivity to olaparib and niraparib (Fig. 3L to N).